The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Sacubitril/valsartan: clinical evidence from PARADIGM-HF

Sacubitril/valsartan: clinical evidence from PARADIGM-HF

Publication date: Thursday, 24 November 2016
Contributor(s): Ameet Bakhai, Andrew R Harper

The large randomised controlled trial PARADIGM-HF showed that treatment with sacubitril/valsartan (Entresto) compared with enalapril reduced the risk of hospitalisation, cardiovascular and all-cause mortality and improved symptoms in patients with heart failure with reduced ejection fraction. This article describes the key results and how they can be applied in primary care.

Sponsorship information:
his sponsored supplement was initiated and funded by Novartis. Novartis reviewed the supplement for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 9 Number 1 Oct-Nov-Dec 2016
Contributor(s): Ameet Bakhai, Andrew R Harper

Article search and filter